Transplantation-associated thrombotic microangiopathy： risk factors and treatment outcome

Liu Jia; Zhu Lidan; Gao Shichun; Liu Huanfeng; Wang Lu; Zhang Cheng; Gao Li; Zhang Xi; Kong Peiyan; Gao Lei

doi:10.13406/j.cnki.cyxb.003543

您当前的位置：

首页 >

文章列表页 >

Transplantation-associated thrombotic microangiopathy： risk factors and treatment outcome

Blood diseases | 更新时间：2025-10-21

- Transplantation-associated thrombotic microangiopathy： risk factors and treatment outcome
- Journal of Chongqing Medical University Vol. 49, Issue 7, Pages: 802-806(2024)
- 作者机构：
  
  陆军军医大学第二附属医院血液病医学中心，重庆 400037
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003543
  CLC： R457.7
- Received：20 June 2024，
  
  Revised：2024-04-17，
  
  Accepted：14 June 2024，
  
  Published：28 July 2024
- 稿件说明：
移动端阅览
刘嘉,朱丽丹,高世春,等.移植相关血栓性微血管病的危险因素及疗效分析[J].重庆医科大学学报,2024,49(7):802-806.

Liu Jia,Zhu Lidan,Gao Shichun,et al.Transplantation-associated thrombotic microangiopathy： risk factors and treatment outcome[J].Journal of Chongqing Medical University,2024,49(7):802-806.
刘嘉,朱丽丹,高世春,等.移植相关血栓性微血管病的危险因素及疗效分析[J].重庆医科大学学报,2024,49(7):802-806. DOI： 10.13406/j.cnki.cyxb.003543.

Liu Jia,Zhu Lidan,Gao Shichun,et al.Transplantation-associated thrombotic microangiopathy： risk factors and treatment outcome[J].Journal of Chongqing Medical University,2024,49(7):802-806. DOI： 10.13406/j.cnki.cyxb.003543.

摘要

目的

研究移植相关血栓性微血管病（transplantation-associated thrombotic microangiopathy，TA-TMA）的临床特征、高危风险因素、治疗方案对TA-TMA的早期诊断以及治疗效果的价值。

方法

选择2019年1月至2023年6月在陆军军医大学第二附属医院血液病医学中心诊断的40例TA-TMA患者作为研究对象，同时选取同一时间段未发生TA-TMA异基因造血干细胞移植的患者120例，回顾性分析TA-TMA患者临床特征、高危风险因素、治疗反应、生存情况等。

结果

二元logistic回归分析结果显示单倍体移植、巨细胞病毒感染、急性移植物抗宿主病、钙调抑制剂浓度增高是TA-TMA发生的高危风险因素（

0.05）；将40例TA-TMA患者的治疗方案分为2组：含血浆置换治疗方案26例（方案1），不含血浆置换治疗方案14例（方案2）。结果显示方案1存活8例（30.8%），方案2存活2例（14.3%），2组疗效差异无统计学意义（

0.05）。

结论

单倍体造血干细胞移植、巨细胞病毒感染、急性移植物抗宿主病是TA-TMA发生的高危风险因素，本研究结果显示含或不含血浆置换方案疗效无显著统计学差异，建议依据患者病情、TA-TMA指南推荐进行治疗选择，后续亟需进一步探索更优的治疗方案，从而改善TA-TMA患者预后，提高患者生存率。

Abstract

Objective

To investigate the effect of the clinical features，high-risk factors，and treatment regimens of transplantation-associated thrombotic microangiopathy（TA-TMA） on the early diagnosis and treatment outcome of TA-TMA.

Methods

A total of 40 patients with TA-TMA who were diagnosed in Hematology Medical Center，The Second Affiliated Hospital of Army Medical University，from January 2019 to June 2023 were enrolled as subjects，and 120 patients who did not experience TA-TMA after allogeneic hematopoietic stem cell transplantation during the same period of time were also enrolled. A retrospective analysis was performed for the clinical features，high-risk factors，treatment response，and survival status of TA-TMA patients.

Results

The binary logistic regression analysis showed that haploidentical transplantation，cytomegalovirus infection，acute graft-versus-host disease，and increased concentrations of calcium regulatory inhibitors were high-risk factors for TA-TMA（

0.05）. According to the treatment regimen，40 patients with TA-TMA were divided into regimen 1 group with 26 patients（with the treatment regimen of plasma exchange） and regimen 2 group with 14 patients（without the treatment regimen of plasma exchange）. The results showed the survival of 8 patients in the regimen 1 group（30.8%） and 2 patients in the regimen 2 group（14.3%），and there was no significant difference in treatment outcome between the two groups（

0.05）.

Conclusion

Haploidentical hematopoietic stem cell transplantation，cytomegalovirus infection，and acute graft-versus-host disease are high-risk factors for TA-TMA. The results of this study show no significant difference in treatment efficacy between the treatment regimens with or without plasma exchange. It is recommended to select treatment regimens according to the patient’s conditions and TA-TMA treatment guidelines，and it is urgent to further explore better treatment regimens to improve the prognosis and survival rate of TA-TMA patients.

关键词

Keywords

references

韩　悦 . 我如何治疗移植相关性血栓性微血管病 [J ] . 中华血液学杂志， 2020 ， 41 （ 4 ）： 272 - 275 ．

Han Y . How I treat transplant-associated thrombotic microangiopathy [J ] . Chin J Hematol ， 2020 ， 41 （ 4 ）： 272 - 275 ．

中华医学会血液学分会造血干细胞应用学组 . 造血干细胞移植相关血栓性微血管病诊断和治疗中国专家共识（2021年版） [J ] . 中华血液学杂志， 2021 ， 42 （ 3 ）： 177 - 184 ．

Hematopoietic stem cell Application Group，Hematology Society，Chinese Medical Association . Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy（2021） [J ] . Chin J Hematol ， 2021 ， 42 （ 3 ）： 177 - 184 ．

Epperla N ， Li A ， Logan B ， et al . Incidence，risk factors for and outcomes of transplant-associated thrombotic microangiopathy [J ] . Br J Haematol ， 2020 ， 189 （ 6 ）： 1171 - 1181 ．

Dvorak CC . TA-TMA：state of the art for diagnosis and treatment [J ] . Blood Adv ， 2020 ， 4 （ 1 ）： 217 ．

Ho VT ， Cutler C ， Carter S ， et al . Blood and marrow transplant clinical trials network toxicity committee consensus summary：thrombotic microangiopathy after hematopoietic stem cell transplantation [J ] . Biol Blood Marrow Transplant ， 2005 ， 11 （ 8 ）： 571 - 575 ．

Laskin BL ， Goebel J ， Davies SM ， et al . Small vessels，big trouble in the kidneys and beyond：hematopoietic stem cell transplantation-associated thrombotic microangiopathy [J ] . Blood ， 2011 ， 118 （ 6 ）： 1452 - 1462 ．

Jodele S ， Laskin BL ， Dandoy CE ， et al . A new paradigm：diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury [J ] . Blood Rev ， 2015 ， 29 （ 3 ）： 191 - 204 ．

莫晓冬，许兰平，刘代红，等 . 急性移植物抗宿主病患者发生移植相关血栓性微血管病的危险因素及预后分析 [J ] . 中华内科杂志， 2013 ， 52 （ 2 ）： 156 - 160 ．

Mo XD ， Xu LP ， Liu DH ， et al . The risk factors and prognosis of transplant-associated thrombotic microangiopathy following acute graft-versus-host disease [J ] . Chin J Intern Med ， 2013 ， 52 （ 2 ）： 156 - 160 ．

Matsui H ， Arai Y ， Imoto H ， etal . Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT [J ] . Blood Adv ， 2024 ， 8 （ 7 ）： 1698 ．

Elfeky R ， Lucchini G ， Lum SH ， et al . New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT [J ] . Blood Adv ， 2020 ， 4 （ 11 ）： 2418 - 2429 ．

Schoettler ML ， Carreras E ， Cho B ， et al . Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy：a report on behalf of the European society for blood and marrow transplantation，American society for transplantation and cellular therapy，Asia-Pacific blood and marrow transplantation group，and center for international blood and marrow transplant research [J ] . Transplant Cell Ther ， 2023 ， 29 （ 3 ）： 151 - 163 ．

Young JA ， Pallas CR ， Knovich MA . Transplant-associated thrombotic microangiopathy：theoretical considerations and a practical approach to an unrefined diagnosis [J ] . Bone Marrow Transplant ， 2021 ， 56 （ 8 ）： 1805 - 1817 ．

Guo MT ， Qi JQ ， Hou QX ， et al . Risk factors for transplant-associated thrombotic microangiopathy（TA-TMA）：a systematic review and meta-analysis [J ] . Expert Rev Hematol ， 2023 ， 16 （ 3 ）： 191 - 203 ．

徐一帆，魏　岩，郭佳媛，等 . 基于不同预后风险模型对移植相关血栓性微血管病的疗效及预后分析 [J ] . 中国实验血液学杂志， 2023 ， 31 （ 5 ）： 1501 - 1508 ．

Xu YF ， Wei Y ， Guo JY ， et al . Efficacy and prognosis of transplant-associated thrombotic microangiopathy based on different prognostic risk models [J ] . J Exp Hematol ， 2023 ， 31 （ 5 ）： 1501 - 1508 ．

陈　峰，吴德沛 . 造血干细胞移植相关的血栓性微血管病的诊断和治疗 [J ] . 中国实用内科杂志， 2023 ， 43 （ 6 ）： 453 - 456 ．

Chen F ， Wu DP . Diagnosis and treatment of transplant-associated thrombotic microangiopathy [J ] . Chin J Pract Intern Med ， 2023 ， 43 （ 6 ）： 453 - 456 ．

Schoettler ML ， Bhatt H ， Vasu S . A systematic review of diagnostic，prognostic，and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy [J ] . Front Immunol ， 2022 ， 13 ： 1064203 ．

Jodele S ， Dandoy CE ， Sabulski A ， et al . Transplantation-associated thrombotic microangiopathy risk stratification：is there a window of opportunity to improve outcomes? [J ] . Transplant Cell Ther ， 2022 ， 28 （ 7 ）： 392.e1 - 392 .e9．

Jodele S ， Dandoy CE ， Aguayo-Hiraldo P ， et al . A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA [J ] . Blood ， 2024 ， 143 （ 12 ）： 1112 - 1123 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment of a nomogram prediction model for severe postpartum hemorrhage in subsequent pregnancies after multiple cesarean sections

Clinical analysis of patients with post-transplant lymphoproliferative disease

Attention to rare and severe complications after hematopoietic stem cell transplantation

Application of WeChat mini-program in improving treatment compliance and outcome of patients with obstructive sleep apnea-hypopnea syndrome receiving continuous positive airway pressure

Effect of hematopoietic stem cell transplantation therapy on lymphocyte subsets and blood cell counts in patients with aplastic anemia

Related Author

Du Xia

Wu Qi

Li Jiarui

Chen Cheng

Zhu Lidan

Liu Jia

Tang Shuhan

Gao Shichun

Related Institution

Department of Health Statistics， School of Preventive Medicine，Army Medical University

Chongqing Medical University/Chongqing General Hospital

Department of Otolaryngology，Chongqing General Hospital/Chongqing General Hospital，Chongqing University

Department of Epidemiology and Health Statistics，School of Public Health，Zhengzhou University

Central Laboratory，The Third People's Hospital of Zhengzhou

⁰